Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Sera Prognostics, Inc. SERA

Healthcare  —  Medical Devices
2.04 (0.07) (3.32%) as of 25 Sep
Market cap
$83.2M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Sera Prognostics, Inc. (SERA) Business Profile

Updated before January 2025

Company Overview

Sera Prognostics, Inc. (SERA) is a leading biotechnology company specializing in the development and commercialization of innovative diagnostic tests aimed at improving maternal and neonatal health. Founded in 2008 and headquartered in Salt Lake City, Utah, Sera Prognostics was established with the mission of advancing pregnancy care through precision medicine. The company’s leadership team includes experienced professionals in biotechnology, diagnostics, and healthcare, with Gregory C. Critchfield, M.D., M.S., serving as Chairman and CEO. Under his guidance, Sera Prognostics has become a pioneer in predictive diagnostics for pregnancy-related complications.

Core Business Segments

Sera Prognostics focuses on developing diagnostic tests that provide actionable insights for healthcare providers to improve pregnancy outcomes. The company’s core business segments include:

1. Predictive Diagnostic Tests

  • PreTRM® Test: Sera’s flagship product, the PreTRM® Test, is a blood-based biomarker test that predicts the risk of preterm birth in asymptomatic singleton pregnancies. This test enables healthcare providers to identify at-risk pregnancies early and implement personalized care strategies to mitigate risks.

2. Research and Development (R&D)

  • Sera Prognostics invests heavily in R&D to discover and validate new biomarkers for pregnancy-related complications, such as preeclampsia and gestational diabetes. The company collaborates with academic institutions and healthcare organizations to expand its diagnostic portfolio.

3. Clinical Partnerships

  • Sera partners with healthcare providers, payers, and research institutions to integrate its diagnostic solutions into clinical practice. These partnerships aim to improve patient outcomes while reducing healthcare costs associated with adverse pregnancy events.

Business Model

Sera Prognostics operates on a business model that combines innovation, collaboration, and commercialization. The company generates revenue through the sale of its PreTRM® Test and related services. Its business model includes:

  • Product Commercialization: Sera markets its PreTRM® Test directly to healthcare providers and through partnerships with healthcare systems and payers.
  • Collaborative Research: The company collaborates with academic and clinical institutions to validate its diagnostic tests and discover new biomarkers.
  • Value-Based Care: By providing predictive insights, Sera helps healthcare providers implement cost-effective, personalized care plans, aligning with the broader shift toward value-based care in the healthcare industry.

Strategic Direction

Sera Prognostics is committed to expanding its diagnostic portfolio and enhancing its impact on maternal and neonatal health. Key strategic initiatives include:

  • Product Expansion: The company is actively researching new biomarkers to develop diagnostic tests for other pregnancy-related complications, such as preeclampsia and stillbirth.
  • Global Market Penetration: Sera aims to expand its presence in international markets, particularly in regions with high rates of preterm birth and limited access to advanced diagnostics.
  • Sustainability Goals: Sera is dedicated to promoting sustainable healthcare practices by reducing the economic and social burden of adverse pregnancy outcomes.
  • Technological Innovation: The company continues to invest in advanced technologies, such as machine learning and artificial intelligence, to enhance the accuracy and predictive power of its diagnostic tests.

Competitive Landscape

Sera Prognostics operates in a competitive market that includes both established diagnostic companies and emerging biotech firms. Key competitors include:

  • PerkinElmer, Inc.: Offers a range of diagnostic solutions, including prenatal screening tests.
  • Natera, Inc.: Specializes in genetic testing and diagnostics for reproductive health.
  • Progenity, Inc.: Focuses on molecular testing for women’s health and reproductive medicine.
  • Thermo Fisher Scientific: Provides a broad portfolio of diagnostic and research tools, including prenatal testing solutions.

Sera differentiates itself through its focus on predictive diagnostics and its commitment to improving pregnancy outcomes.

Risk Factors

Sera Prognostics faces several risks that could impact its business operations and financial performance:

  • Market Dependence: The company relies heavily on the success of its PreTRM® Test, making it vulnerable to market fluctuations and competitive pressures.
  • Regulatory Challenges: As a diagnostic company, Sera must navigate complex regulatory environments in different markets, which could delay product approvals and commercialization.
  • Supply Chain Disruptions: Dependence on third-party suppliers for raw materials and manufacturing could lead to disruptions in product availability.
  • Reimbursement Risks: The adoption of Sera’s diagnostic tests depends on securing reimbursement from payers, which can be a lengthy and uncertain process.

Recent Developments

Sera Prognostics has made significant strides in recent years, including:

  • Expanded Clinical Validation: The company published new clinical studies demonstrating the efficacy of the PreTRM® Test in predicting preterm birth and improving pregnancy outcomes.
  • Partnerships: Sera entered into strategic partnerships with major healthcare systems to integrate its diagnostic solutions into routine prenatal care.
  • Technological Advancements: The company adopted advanced data analytics and machine learning techniques to enhance the predictive accuracy of its tests.
  • COVID-19 Impact: While the pandemic posed challenges, it also highlighted the importance of predictive diagnostics in managing healthcare resources effectively.

Investment Considerations

Strengths:

  • Innovative Product Portfolio: Sera’s focus on predictive diagnostics sets it apart in the maternal health market.
  • Strong Leadership: The company benefits from an experienced management team with a proven track record in biotechnology and diagnostics.
  • Market Potential: With rising awareness of maternal health issues, Sera is well-positioned to capture a growing market.

Risks:

  • Product Dependence: Heavy reliance on the PreTRM® Test could limit growth if the product faces market or regulatory challenges.
  • Competitive Pressure: The diagnostics market is highly competitive, with established players and new entrants vying for market share.
  • Regulatory and Reimbursement Hurdles: Delays in regulatory approvals or reimbursement decisions could impact revenue growth.

Conclusion

Sera Prognostics, Inc. is a trailblazer in the field of predictive diagnostics for maternal and neonatal health. With its innovative PreTRM® Test and a strong commitment to research and development, the company is well-positioned to address critical unmet needs in pregnancy care. While it faces challenges such as market dependence and regulatory hurdles, Sera’s strategic initiatives and focus on innovation provide a solid foundation for future growth. As the demand for precision medicine continues to rise, Sera Prognostics is poised to play a pivotal role in shaping the future of maternal health diagnostics.